Correction to: Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China (BMC Medicine, (2015), 13, 1, (237), 10.1186/s12916-015-0495-0);Idiopathic pulmonary fibrosis in BRIC countries: The cases of Brazil, Russia, India, and China

BMC Medicine

Volumn 13, Issue 1, 2015, Pages 2-

  Richeldi, Luca ^a   Rubin, Adalberto Sperb ^b   Avdeev, Sergey ^c   Udwadia, Zarir F ^d,e   Xu, Zuo Jun ^f  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c Research Institute of Pulmonology   (Russian Federation)

^d P D HINDUJA NATIONAL HOSPITAL   (India)

^e BREACH CANDY HOSPITAL   (India)

^f PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

BRIC countries; High resolution computed tomography; Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidone

Indexed keywords

ACETYLCYSTEINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PIRFENIDONE;

ARTICLE; BRAZIL; CHINA; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; INDIA; INTERNATIONAL COOPERATION; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; OXYGEN THERAPY; PREDICTION; PREVALENCE; RURAL AREA; RUSSIAN FEDERATION; SYMPTOM; TEACHING HOSPITAL; GENETICS; PROCEDURES; PROGNOSIS; X-RAY COMPUTED TOMOGRAPHY;

BRAZIL; CHINA; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDIA; PROGNOSIS; RUSSIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85031874930     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-021-02111-4     Document Type: Erratum

References (43)

1. Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Myllarniemi M. Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med. 2013;13:53.
2. Esposito DB, Lanes S, Donneyong M, Holick CN, Lasky JA, Lederer D, et al. Idiopathic pulmonary fibrosis in US automated claims: incidence, prevalence and algorithm validation. Am J Respir Crit Care Med. 2015. Ahead of print.
3. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372:1189-91.
4. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079-87.
5. Fortuna FP, Perin C, Cunha L, Rubin AS. Mortality due to idiopathic pulmonary fibrosis in the State of Rio Grande do Sul (Brazil). J Bras Pneumol. 2003;29:121-4. In Portuguese.
6. Baldi BG, Pereira CA, Rubin AS, Santana AN, Costa AN, Carvalho CR, et al. Highlights of the Brazilian Thoracic Association guidelines for interstitial lung diseases. J Bras Pneumol. 2012;38:282-91.
7. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King Jr TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968-77.
8. Lima MS, Coletta EN, Ferreira RG, Jasinowodolinski D, Arakaki JS, Rodrigues SC, et al. Subacute and chronic hypersensitivity pneumonitis: histopathological patterns and survival. Respir Med. 2009;103:508-15.
9. Pereira CA, Malheiros T, Coletta EM, Ferreira RG, Rubin AS, Otta JS, et al. Survival in idiopathic pulmonary fibrosis-cytotoxic agents compared to corticosteroids. Respir Med. 2006;100:340-7.
10. Bandeira CD, Rubin AS, Cardoso PF, Moreira Jda S, Machado Mda M. Prevalence of gastroesophageal reflux disease in patients with idiopathic pulmonary fibrosis. J Bras Pneumol. 2009;35:1182-9.
11. Florian J, Rubin A, Mattiello R, Fontoura FF, Camargo Jde J, Teixeira PJ. Impact of pulmonary rehabilitation on quality of life and functional capacity in patients on waiting lists for lung transplantation. J Bras Pneumol. 2013;39:349-56.
12. Machuca TN, Schio SM, Camargo SM, Lobato V, Costa CD, Felicetti JC, et al. Prognostic factors in lung transplantation: the Santa Casa de Porto Alegre experience. Transplantation. 2011;91:1297-303.
13. King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-92.
14. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82.
15. Petrov DV, Ovsjannikov NV, Kapralov EA, Kapustian OV. Interstitial lung diseases: point of view of practical doctor. Practical Pulmonol. 2014;1:32-8. In Russian.
16. Chuchalin AG. Idiopathic pulmonary fibrosis. Ther Archive. 2000;3:5-12. In Russian.
17. Ilkovich MM, Novikova LN, Koroleva MG. Idiopathic fibrosing alveolitis: controversies in modern presentations. Pulmonology. 2003;3:98-101. In Russian.
18. Kotlyarov PM, Georgiadi SG. New technologies and progress of imaging of diffuse interstitial lung diseases. Pulmonology. 2005;6:61-9. In Russian.
19. Avdeev SN. Idiopathic pulmonary fibrosis: current concepts and diagnostic approaches. Practical Pulmonology. 2014;4:16-23. In Russian.
20. Avdeev SN. Idiopathic pulmonary fibrosis: approaches to the diagnosis and treatment in Russia. Pulmonology. 2015. Ahead of print. In Russian.
21. Khubutia MS, Chuchalin AG, Abakumov MM, Avdeev SN, Timerbaev VK, Poplavsky IV, et al. The first lung transplantation at the Research Institute of Emergency named after N.V. Sklifosovsky. Transplantation. 2011;2:5-9. In Russian.
22. Jindal SK, Malik SK, Deodhar SD, Sharma BK. Fibrosing alveolitis: a report of 61 cases seen over the past five years. Indian J Chest Dis Allied Sci. 1979;21:174-9.
23. Mahashur AA, Dave KM, Kinare SG, Kamat SR, Shetye VM, Kolhatkar VP. Diffuse fibrosing alveolitis - an Indian experience. Lung India. 1983;5:171-9.
24. Sharma SK, Pande JN, Verma K, Guleria JS. Bronchoalveolar lavage fluid (BALF) analysis in interstitial lung diseases--a 7-year experience. Indian J Chest Dis Allied Sci. 1989;31:187-96.
25. Maheshwari U, Gupta D, Aggarwal AN, Jindal SK. Spectrum and diagnosis of idiopathic pulmonary fibrosis. Indian J Chest Dis Allied Sci. 2004;46:23-6.
26. Subhash HS, Ashwin I, Solomon SK, David T, Cherian AM, Thomas K. A comparative study on idiopathic pulmonary fibrosis and secondary diffuse parenchymal lung disease. Indian J Med Sci. 2004;58:185-90.
27. Sen T, Udwadia ZF. Retrospective study of interstitial lung disease in a tertiary care centre in India. Indian J Chest Dis Allied Sci. 2010;52:207-11.
28. Kundu S, Mitra S, Ganguly J, Mukherjee S, Ray S, Mitra R. Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience. Lung India. 2014;31:354-60.
29. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980-5.
30. Udwadia ZF, Sen T, Jindal SK. Interstitial lung diseases in a resource-limited setting: the case of India. In: du Bois RM, Richeldi L, editors. European Respiratory Monograph 46: Interstitial Lung Diseases. Sheffield: European Respiratory Society Journals Ltd; 2009. p. 357-74.
31. Singh V, Sharma BB. Laying the ground for research of interstitial lung disease in our country: ILD India registry. Lung India. 2014;31:320-2.
32. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192:e3-19.
33. Interstitial Lung Disease Group of Chinese Society of Respiratory Disease. Summary of the sixth national symposium on respiratory diseases in China. Zhong hua Jie He He Hu Xi Za Zhi. 2004;27:858-61. In Chinese.
34. Li HP, Huang JA, Fan F, Li X, Yu H, Zhao L, et al. Clinical analysis of 395 patients with diffuse lung diseases. Shanghai Med J. 2007;30:665-8. In Chinese.
35. Yang XM, Wang CZ, Cui SH, Liu Z, Li XJ, Du XZ. Retrospective analysis of diffuse interstitial lung disease cases admitted in 5 teaching hospitals in Chongqing. Chin J Respir Crit Care Med. 2008;7:120-3. In Chinese.
36. Wei LQ, Peng SC, Cao J, Liu GY, Lai YP, Jia W, et al. Clinical features and diagnosis and treatment of diffuse interstitial lung disease: a multi-center study. Chinese General Practice. 2012;15:2521-4. In Chinese.
37. Zhang D, Liu Y. Surgical lung biopsies in 418 patients with suspected interstitial lung disease in China. Intern Med. 2010;49:1097-102.
38. Ji Y, Wang T, Wei ZF, Lu GX, Jiang SD, Xia YF, et al. Paeoniflorin, the main active constituent of Paeonia lactiflora roots, attenuates bleomycin-induced pulmonary fibrosis in mice by suppressing the synthesis of type I collagen. J Ethnopharmacol. 2013;149:825-32.
39. He H, Tang H, Gao L, Wu Y, Feng Z, Lin H, et al. Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis in rats. Mol Med Rep. 2015;11:4190-6.
40. Li L, Li D, Xu L, Zhao P, Deng Z, Mo X, et al. Total extract of Yupingfeng attenuates bleomycin-induced pulmonary fibrosis in rats. Phytomedicine. 2015;22:111-9.
41. Xu H, Li S. Pharmacological effects of Bailing capsule and its application in lung disease research. Zhongguo Zhong Yao Za Zhi. 2010;35:2777-81. In Chinese.
42. Zhang W, Jiang LD, Zhang XM, Wu JJ, Deng Y, Lu XF. Influence of feixian formula on serum transforming growth factor-beta1 and platelet-derived growth factor in rats with bleomycin-induced pulmonary fibrosis. Zhong Xi Yi Jie He Xue Bao. 2008;6:595-9. In Chinese.
43. Mao W, Chen J, Zheng M, Wu B, Zhu Y. Initial experience of lung transplantation at a single center in China. Transplant Proc. 2013;45:349-55.